Sylvie Négrier
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Renal cell carcinoma treatment
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 104
- Oncology 57
- Cancer Immunotherapy and Biomarkers 26
- Cancer Diagnosis and Treatment 9
- Pancreatic and Hepatic Oncology Research 8
- Co-authors
- Ronald M. Bukowski (12 shared papers)Thomas E. Hutson (10 shared papers)Stéphane Marie. Oudard (19 shared papers)Cezary A. Szczylik (10 shared papers)Bernard J. Escudier (58 shared papers)Robert John Motzer (19 shared papers)Marc Dror Michaelson (10 shared papers)Piotr Tomczak (5 shared papers)
- Journals
- Annals of Oncology (30 papers)Journal of Clinical Oncology (24 papers)European Journal of Cancer (14 papers)British Journal of Cancer (13 papers)Clinical Genitourinary Cancer (6 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Sylvie Négrier
198 papers receiving 25.9k citations
Sylvie Négrier's Hit Papers
Peers
Comparison fields: 5 of 144
- Pulmonary and Respiratory Medicine 15.3k
- Cancer Research 5.7k
- Oncology 8.2k
- Molecular Biology 9.4k
- Immunology 2.2k
Countries citing papers authored by Sylvie Négrier
This map shows the geographic impact of Sylvie Négrier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Négrier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Négrier more than expected).
Fields of papers citing papers by Sylvie Négrier
This network shows the impact of papers produced by Sylvie Négrier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Négrier. The network helps show where Sylvie Négrier may publish in the future.
Co-authors
The 25 scholars most cited alongside Sylvie Négrier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 206 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4810 |
| 2 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4078 |
| 3 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 1971 |
| 4 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1843 |
| 5 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Hit paper breakdown → | 2011 | 1544 |
| 6 | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Hit paper breakdown → | 2009 | 1033 |
| 7 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Hit paper breakdown → | 2009 | 934 |
| 8 | Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 1998 | 783 |
| 9 | Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival Hit paper breakdown → | 2010 | 685 |
| 10 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Hit paper breakdown → | 2013 | 610 |
| 11 | Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 406 |
| 12 | 1997 | 383 | |
| 13 | 2007 | 334 | |
| 14 | 2002 | 298 | |
| 15 | 2008 | 212 | |
| 16 | 1997 | 203 | |
| 17 | 1999 | 202 | |
| 18 | 2011 | 197 | |
| 19 | 2010 | 165 | |
| 20 | 2011 | 157 |
About Sylvie Négrier
Sylvie Négrier is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Ophthalmology, having authored 206 papers that have together received 26.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (104 papers), Cancer Immunotherapy and Biomarkers (26 papers), Renal and related cancers (26 papers), Cancer Genomics and Diagnostics (17 papers), Bladder and Urothelial Cancer Treatments (16 papers), Cancer Diagnosis and Treatment (9 papers), Economic and Financial Impacts of Cancer (8 papers) and Pancreatic and Hepatic Oncology Research (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (15.3k citations), Cancer Research (5.7k citations), Oncology (8.2k citations), Molecular Biology (9.4k citations) and Immunology (2.2k citations). Sylvie Négrier has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Ronald M. Bukowski, Thomas E. Hutson, Stéphane Marie. Oudard, Cezary A. Szczylik, Bernard J. Escudier, Robert John Motzer, Marc Dror Michaelson, Piotr Tomczak, Robert A. Figlin and Sindy T. Kim. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, British Journal of Cancer and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.